Clinical Trial Update: Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects [Phase 3]

View source ↗

Summary

A Phase 3 repeat-dose safety study in epilepsy subjects has completed, with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• NRL-1

Snippet

Sponsor: Neurelis, Inc. | Conditions: Acute Repetitive Seizures, Breakthrough Seizures | Phase 3 | Status: COMPLETED | Results posted: 2022-01-31